{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:25Z","timestamp":1791207325350,"version":"4.1.0"},"reference-count":322,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017473","name":"Australian Genomics Health Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001786","name":"University of Adelaide","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from immature lymphocytes that show uncontrolled proliferation and arrested differentiation. Genomic alterations affecting Janus kinase 2 (<jats:italic>JAK2<\/jats:italic>) correlate with some of the poorest outcomes within the Philadelphia-like subtype of ALL. Given the success of kinase inhibitors in the treatment of chronic myeloid leukemia, the discovery of activating <jats:italic>JAK2<\/jats:italic> point mutations and <jats:italic>JAK2<\/jats:italic> fusion genes in ALL, was a breakthrough for potential targeted therapies. However, the molecular mechanisms by which these alterations activate JAK2 and promote downstream signaling is poorly understood. Furthermore, as clinical data regarding the limitations of approved JAK inhibitors in myeloproliferative disorders matures, there is a growing awareness of the need for alternative precision medicine approaches for specific <jats:italic>JAK2<\/jats:italic> lesions. This review focuses on the molecular mechanisms behind ALL-associated <jats:italic>JAK2<\/jats:italic> mutations and <jats:italic>JAK2<\/jats:italic> fusion genes, known and potential causes of JAK-inhibitor resistance, and how <jats:italic>JAK2<\/jats:italic> alterations could be targeted using alternative and novel rationally designed therapies to guide precision medicine approaches for these high-risk subtypes of ALL.<\/jats:p>","DOI":"10.3389\/fcell.2022.942053","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T10:14:30Z","timestamp":1657620870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies"],"prefix":"10.3389","volume":"10","author":[{"given":"Charlotte EJ.","family":"Downes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"McDougal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Heatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Bruning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","article-title":"Efficacy of Vorinostat in a Murine Model of Polycythemia Vera","volume":"119","author":"Akada","year":"2012","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells","volume":"32","author":"Akada","year":"2014","journal-title":"Stem Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40291-016-0208-1","article-title":"Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy","volume":"20","author":"Ali","year":"2016","journal-title":"Mol. Diagn Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythaemia Vera and Essential Thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2159-8290.cd-11-0324","article-title":"Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent","volume":"2","author":"Andraos","year":"2012","journal-title":"Cancer Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/s0140-6736(13)62120-0","article-title":"Chronic Myeloid Leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib Inhibits ACVR1\/ALK2, Decreases Hepcidin Production, and Ameliorates Anemia of Chronic Disease in Rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","article-title":"STAT Proteins: a Kaleidoscope of Canonical and Non-canonical Functions in Immunity and Cancer","volume":"14","author":"Awasthi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/j.1460-2075.1995.tb07126.x","article-title":"Interleukin-3 Signals through Multiple Isoforms of Stat5","volume":"14","author":"Azam","year":"1995","journal-title":"EMBO J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20140712","article-title":"The Molecular Regulation of Janus Kinase (JAK) Activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jmb.2008.06.038","article-title":"The SOCS Box Domain of SOCS3: Structure and Interaction with the elonginBC-Cullin5 Ubiquitin Ligase","volume":"381","author":"Babon","year":"2008","journal-title":"J. Mol. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jmb.2009.01.024","article-title":"The SOCS Box Encodes a Hierarchy of Affinities for Cullin5: Implications for Ubiquitin Ligase Formation and Cytokine Signalling Suppression","volume":"387","author":"Babon","year":"2009","journal-title":"J. Mol. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal Structures of the JAK2 Pseudokinase Domain and the Pathogenic Mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood.v97.8.2230","article-title":"A Common Epitope Is Shared by Activated Signal Transducer and Activator of Transcription-5 (STAT5) and the Phosphorylated Erythropoietin Receptor: Implications for the Docking Model of STAT Activation","volume":"97","author":"Barber","year":"2001","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/jco.2010.28.1287","article-title":"Chemotherapy-phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"Jco"},{"key":"B16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/tcrm.s258704","article-title":"Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate\/High-Risk Myelofibrosis: Evidence to Date","volume":"16","author":"Bassiony","year":"2020","journal-title":"Tcrm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(05)71142-9","article-title":"Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/ijc.23467","article-title":"Targeting of the N-Terminal Coiled Coil Oligomerization Interface by a Helix-2 Peptide Inhibits Unmutated and Imatinib-Resistant BCR\/ABL","volume":"122","author":"Beissert","year":"2008","journal-title":"Int. J. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","article-title":"Signal Transducer and Activator of Transcription Proteins in Leukemias","volume":"101","author":"Benekli","year":"2003","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/s0140-6736(08)61341-0","article-title":"Mutations of JAK2 in Acute Lymphoblastic Leukaemias Associated with Down's Syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.2147\/cmar.s212559","article-title":"Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis","volume":"11","author":"Bewersdorf","year":"2019","journal-title":"Cmar"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved Targeting of JAK2 Leads to Increased Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"123","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted Cancer Therapies: Progress, Challenges and Future Directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"D344","DOI":"10.1093\/nar\/gkaa977","article-title":"The InterPro Protein Families and Domains Database: 20 Years on","volume":"49","author":"Blum","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.3324\/haematol.2015.124941","article-title":"BCR-ABL1-like Cases in Pediatric Acute Lymphoblastic Leukemia: A Comparison between DCOG\/Erasmus MC and COG\/St. Jude Signatures","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.06.012","article-title":"BCR-ABL1 -like Acute Lymphoblastic Leukaemia: From Bench to Bedside","volume":"82","author":"Boer","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine Kinase Fusion Genes in Pediatric BCR-ABL1-like Acute Lymphoblastic Leukemia","volume":"8","author":"Boer","year":"2017","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1038\/s41375-021-01248-8","article-title":"Combination Efficacy of Ruxolitinib with Standard-Of-Care Drugs in CRLF2-Rearranged Ph-like Acute Lymphoblastic Leukemia","volume":"35","author":"B\u04e7hm","year":"2021","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e28087","DOI":"10.4161\/jkst.28087","article-title":"Protein Tyrosine Phosphatases as Wardens of STAT Signaling","volume":"3","author":"B\u00f6hmer","year":"2014","journal-title":"JAK-STAT"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1080\/10428194.2018.1543876","article-title":"A Phase 2 Study of Pracinostat Combined with Ruxolitinib in Patients with Myelofibrosis","volume":"60","author":"Bose","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/hs9.0000000000000424","article-title":"JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"Hemasphere"},{"key":"B32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 Inhibitors for Myeloproliferative Neoplasms: what Is Next?","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010240","article-title":"Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers","volume":"12","author":"Brachet-Botineau","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine Kinase Inhibitors Improve Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1097\/hs9.0000000000000516","article-title":"Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms","volume":"5","author":"Brkic","year":"2021","journal-title":"Hemasphere"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1021\/mp500701u","article-title":"Inhibition of Bcr-Abl in Human Leukemic Cells with a Coiled-Coil Protein Delivered by a Leukemia-specific Cell-Penetrating Peptide","volume":"12","author":"Bruno","year":"2015","journal-title":"Mol. Pharm."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.3324\/haematol.2014.114447","article-title":"Fine Tuning of Surface CRLF2 Expression and its Associated Signaling Profile in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"100","author":"Bugarin","year":"2015","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","article-title":"Does Ruxolitinib Prolong the Survival of Patients with Myelofibrosis?","volume":"129","author":"Cervantes","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized Study of Reduced-Intensity Chemotherapy Combined with Imatinib in Adults with Ph-Positive Acute Lymphoblastic Leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus Kinases in CRLF2-Rearranged Acute Lymphoblastic Leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3324\/haematol.2012.067959","article-title":"Ruxolitinib as Potential Targeted Therapy for Patients with JAK2 Rearrangements","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1021\/bi036109b","article-title":"Tyrosine Phosphorylation of the Janus Kinase 2 Activation Loop Is Essential for a High-Activity Catalytic State but Dispensable for a Basal Catalytic State","volume":"43","author":"Chatti","year":"2004","journal-title":"Biochemistry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2019.07.065","article-title":"Roles of T875N Somatic Mutation in the Activity, Structural Stability of JAK2 and the Transformation of OCI-AML3 Cells","volume":"137","author":"Chen","year":"","journal-title":"Int. J. Biol. Macromol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1110","DOI":"10.1002\/mgg3.1110","article-title":"Identification of RNPC3 as a Novel JAK2 Fusion Partner Gene in B-Acute Lymphoblastic Leukemia Refractory to Combination Therapy Including Ruxolitinib","volume":"8","author":"Chen","year":"","journal-title":"Mol. Genet. Genomic Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-021-00504-5","article-title":"Fusion Gene Map of Acute Leukemia Revealed by Transcriptome Sequencing of a Consecutive Cohort of 1000 Cases in a Single Center","volume":"11","author":"Chen","year":"2021","journal-title":"Blood Cancer J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/gcc.22995","article-title":"Sustained Remission after Ruxolitinib and Chimeric Antigen Receptor T\u2010cell Therapy Bridged to a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Philadelphia Chromosome\u2010like B\u2010cell Precursor Acute Lymphoblastic Leukemia with Novel NPHP3\u2010JAK2 Fusion","volume":"61","author":"Chen","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"106753","DOI":"10.18632\/oncotarget.22053","article-title":"The Effect of the JAK2 Inhibitor TG101209 against T Cell Acute Lymphoblastic Leukemia (T-ALL) Is Mediated by Inhibition of JAK-STAT Signaling and Activation of the Crosstalk between Apoptosis and Autophagy Signaling","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","article-title":"Givinostat: an Emerging Treatment for Polycythemia Vera","volume":"29","author":"Chifotides","year":"2020","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase Drug Discovery 20 Years after Imatinib: Progress and Future Directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B50","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ajh.24775","article-title":"A Life-Threatening Ruxolitinib Discontinuation Syndrome","volume":"92","author":"Coltro","year":"2017","journal-title":"Am. J. Hematol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1582-4934.2008.00666.x","article-title":"A New Era for Small Molecule Screening: from New Targets, Such as JAK2 V617F, to Complex Cellular Screens","volume":"13","author":"Constantinescu","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1073\/pnas.081069198","article-title":"Ligand-independent Oligomerization of Cell-Surface Erythropoietin Receptor Is Mediated by the Transmembrane Domain","volume":"98","author":"Constantinescu","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41467-020-20400-z","article-title":"BET Inhibition Disrupts Transcription but Retains Enhancer-Promoter Contact","volume":"12","author":"Crump","year":"2021","journal-title":"Nat. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e32451","DOI":"10.1371\/journal.pone.0032451","article-title":"Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase","volume":"7","author":"Cuesta-Dom\u00ednguez","year":"2012","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive Analysis of Kinase Inhibitor Selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.leukres.2012.04.010","article-title":"ETV6 Fusion Genes in Hematological Malignancies: A Review","volume":"36","author":"De Braekeleer","year":"2012","journal-title":"Leukemia Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The Effect of Long-Term Ruxolitinib Treatment on JAK2p.V617F Allele Burden in Patients with Myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s1470-2045(08)70339-5","article-title":"A Subtype of Childhood Acute Lymphoblastic Leukaemia with Poor Treatment Outcome: a Genome-wide Classification Study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2011.255","article-title":"Kinase Domain Mutations Confer Resistance to Novel Inhibitors Targeting JAK2V617F in Myeloproliferative Neoplasms","volume":"26","author":"Deshpande","year":"2012","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical Efficacy of Ruxolitinib and Chemotherapy in a Child with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia with GOLGA5-JAK2 Fusion and Induction Failure","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1021\/mp200461s","article-title":"Improved Coiled-Coil Design Enhances Interaction with Bcr-Abl and Induces Apoptosis","volume":"9","author":"Dixon","year":"2012","journal-title":"Mol. Pharm."},{"key":"B62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41698-021-00215-x","article-title":"Acquired JAK2 Mutations Confer Resistance to JAK Inhibitors in Cell Models of Acute Lymphoblastic Leukemia","volume":"5","author":"Downes","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/bjh.17910","article-title":"Identification of a Novel GOLGA4-JAK2 Fusion Gene in B\u2010cell Acute Lymphoblastic Leukaemia","volume":"196","author":"Downes","year":"2022","journal-title":"Br. J. Haematol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/nejmoa062867","article-title":"Five-year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/jci9083","article-title":"Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J. Clin. Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e11157","DOI":"10.1371\/journal.pone.0011157","article-title":"JAK2 V617F Constitutive Activation Requires JH2 Residue F595: a Pseudokinase Domain Target for Specific Inhibitors","volume":"5","author":"Dusa","year":"2010","journal-title":"PLoS One"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.3324\/haematol.2017.166439","article-title":"p.Y317H Is a New JAK2 Gain-Of-Function Mutation Affecting the FERM Domain in a Myelofibrosis Patient with CALR Mutation","volume":"102","author":"Eder-Azanza","year":"2017","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1755-8166-5-23","article-title":"BCR-JAK2 Fusion as a Result of a Translocation (9;22)(p24;q11.2) in a Patient with CML-like Myeloproliferative Disease","volume":"5","author":"Elnaggar","year":"2012","journal-title":"Mol. Cytogenet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1158\/1078-0432.ccr-13-0905","article-title":"JAK1\/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"669363","DOI":"10.3389\/fcell.2021.669363","article-title":"JAK-STAT in Early Hematopoiesis and Leukemia","volume":"9","author":"Fasouli","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/mcb.17.5.2497","article-title":"Activation of Jak2 Catalytic Activity Requires Phosphorylation of Y1007 in the Kinase Activation Loop","volume":"17","author":"Feng","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: Addition of Imatinib to a Standard Treatment Regimen Enhances Long-Term Outcomes in Philadelphia Positive Acute Lymphoblastic Leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1158\/1078-0432.ccr-11-1541","article-title":"Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3324\/haematol.2015.125336","article-title":"A Novel Xenograft Model to Study the Role of TSLP-Induced CRLF2 Signals in Normal and Malignant Human B Lymphopoiesis","volume":"101","author":"Francis","year":"2016","journal-title":"Haematologica"},{"key":"B76","doi-asserted-by":"publisher","first-page":"12680","DOI":"10.1074\/jbc.m808879200","article-title":"The Acute Lymphoblastic Leukemia-Associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice","volume":"284","author":"Funakoshi-Tago","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-7771-1-5","article-title":"Dysregulation of JAK-STAT Pathway in Hematological Malignancies and JAK Inhibitors for Clinical Application","volume":"1","author":"Furqan","year":"2013","journal-title":"Biomark. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","article-title":"Prevalence and Clinical Correlates ofJAK2mutations in Down Syndrome Acute Lymphoblastic Leukaemia","volume":"144","author":"Gaikwad","year":"2009","journal-title":"Br. J. Haematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9858","DOI":"10.1073\/pnas.152294299","article-title":"Ligand-independent Growth Hormone Receptor Dimerization Occurs in the Endoplasmic Reticulum and Is Required for Ubiquitin System-dependent Endocytosis","volume":"99","author":"Gent","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/j.clml.2018.06.025","article-title":"Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients with Myelofibrosis: A Case Series","volume":"18","author":"Gerds","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B82","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2019-129293","article-title":"Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ajh.23637","article-title":"Restoration of Response to Ruxolitinib upon Brief Withdrawal in Two Patients with Myelofibrosis","volume":"89","author":"Gisslinger","year":"2014","journal-title":"Am. J. Hematol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus Kinase Cytokine Receptor Complex Reveals the Basis for Dimeric Activation","volume":"10","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.2174\/092986711797379267","article-title":"A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road Not Taken","volume":"18","author":"Gnanasambandan","year":"2011","journal-title":"Cmc"},{"key":"B86","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The Ruxolitinib Effect: Understanding How Molecular Pathogenesis and Epigenetic Dysregulation Impact Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J. Transl. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.3324\/haematol.2013.100016","article-title":"Selective Deletion of Jak2 in Adult Mouse Hematopoietic Cells Leads to Lethal Anemia and Thrombocytopenia","volume":"99","author":"Grisouard","year":"2014","journal-title":"Haematologica"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/jci76094","article-title":"Targeting Cancer with Kinase Inhibitors","volume":"125","author":"Gross","year":"2015","journal-title":"J. Clin. Invest."},{"key":"B89","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven Subtypes of B-Progenitor Acute Lymphoblastic Leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/jop.19.00506","article-title":"Patterns of Ruxolitinib Therapy Failure and its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group","volume":"16","author":"Gupta","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1073\/pnas.1423201112","article-title":"ATP Binding to the Pseudokinase Domain of JAK2 Is Critical for Pathogenic Activation","volume":"112","author":"Hammar\u00e9n","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jaci.2018.07.022","article-title":"Janus Kinase 2 Activation Mechanisms Revealed by Analysis of Suppressing Mutations","volume":"143","author":"Hammar\u00e9n","year":"","journal-title":"J. Allergy Clin. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The Regulation of JAKs in Cytokine Signaling and its Breakdown in Disease","volume":"118","author":"Hammar\u00e9n","year":"","journal-title":"Cytokine"},{"key":"B94","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1006\/cimm.1995.1185","article-title":"Bone Marrow B Lymphocyte Development in C-Abl-Deficient Mice","volume":"165","author":"Hardin","year":"1995","journal-title":"Cell. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/nejmoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of Myelofibrosis after Ruxolitinib Failure","volume":"99","author":"Harrison","year":"","journal-title":"Ann. Hematol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/s2352-3026(17)30088-1","article-title":"Janus Kinase-2 Inhibitor Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib (JAKARTA-2): a Single-Arm, Open-Label, Non-randomised, Phase 2, Multicentre Study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: An Updated Analysis of the JAKARTA2 Study Using Stringent Criteria for Ruxolitinib Failure","volume":"95","author":"Harrison","year":"","journal-title":"Am. J. Hematol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/s2352-3026(17)30237-5","article-title":"Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib (SIMPLIFY 2): a Randomised, Open-Label, Phase 3 Trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term Findings from COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"B101","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 Is Associated with Mutation of JAK Kinases, Alteration of IKZF1, Hispanic\/Latino Ethnicity, and a Poor Outcome in Pediatric B-Progenitor Acute Lymphoblastic Leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical Diagnostics and Treatment Strategies for Philadelphia Chromosome-like Acute Lymphoblastic Leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv."},{"key":"B103","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cancergen.2016.03.002","article-title":"BCR-JAK2 Fusion in a Myeloproliferative Neoplasm with Associated Eosinophilia","volume":"209","author":"He","year":"2016","journal-title":"Cancer Genet."},{"key":"B104","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia Frequently Have IGH-CRLF2 and JAK2 Mutations, Persistence of Minimal Residual Disease and Poor Prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematologica"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down Syndrome Acute Lymphoblastic Leukemia, a Highly Heterogeneous Disease in Which Aberrant Expression of CRLF2 Is Associated with Mutated JAK2: a Report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"B106","first-page":"107","article-title":"JAK2 Translocations in Hematological Malignancies: Review of the Literature","volume":"36","author":"Ho","year":"2010","journal-title":"J. Assoc. Genet. Technol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.3324\/haematol.2017.177600","article-title":"Hsp90 Inhibition Disrupts JAK-STAT Signaling and Leads to Reductions in Splenomegaly in Patients with Myeloproliferative Neoplasms","volume":"103","author":"Hobbs","year":"2018","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B109","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/nejmoa1609324","article-title":"Long-term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.seminhematol.2017.04.005","article-title":"ETV6 in Hematopoiesis and Leukemia Predisposition","volume":"54","author":"Hock","year":"2017","journal-title":"Seminars Hematol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3324\/haematol.2010.036350","article-title":"Oncogenic JAK1 and JAK2-Activating Mutations Resistant to ATP-Competitive Inhibitors","volume":"96","author":"Hornakova","year":"2011","journal-title":"Haematologica"},{"key":"B112","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12308-020-00413-9","article-title":"TBL1XR1-JAK2: a Novel Fusion in a Pediatric T Cell Acute Lymphoblastic Leukemia Patient with Increased Absolute Eosinophil Count","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematop."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2017.00361","article-title":"Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase","volume":"8","author":"Hubbard","year":"2018","journal-title":"Front. Endocrinol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/nejmoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/nejmra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/genes12050687","article-title":"Genetic Alterations and Therapeutic Targeting of Philadelphia-like Acute Lymphoblastic Leukemia","volume":"12","author":"Iacobucci","year":"2021","journal-title":"Genes (Basel)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/jco.2016.70.7836","article-title":"Genetic Basis of Acute Lymphoblastic Leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"Jco"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1038\/bcj.2016.28","article-title":"Characterization of Pediatric Philadelphia-negative B-Cell Precursor Acute Lymphoblastic Leukemia with Kinase Fusions in Japan","volume":"6","author":"Imamura","year":"2016","journal-title":"Blood Cancer J."},{"key":"B119","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in Pediatric Acute Lymphoblastic Leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"B120","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/35053086","article-title":"CD45 Is a JAK Phosphatase and Negatively Regulates Cytokine Receptor Signalling","volume":"409","author":"Irie-Sasaki","year":"2001","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/ar1197","article-title":"Signaling by STATs","volume":"6","author":"Ivashkiv","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/gcc.22076","article-title":"Genome\u2010wide Identification of Genes with Amplification And\/or Fusion in Small Cell Lung Cancer","volume":"52","author":"Iwakawa","year":"2013","journal-title":"Genes Chromosom. Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New Insights into the Pathophysiology and Therapy of Adult Acute Lymphoblastic Leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like Acute Lymphoblastic Leukemia: a High-Risk Subtype in Adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1947601910371337","article-title":"A Non-ATP-competitive Dual Inhibitor of JAK2V617F and BCR-Ablt315i Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition","volume":"1","author":"Jatiani","year":"2010","journal-title":"Genes & Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/bioinformatics\/btu031","article-title":"InterProScan 5: Genome-Scale Protein Function Classification","volume":"30","author":"Jones","year":"2014","journal-title":"Bioinformatics"},{"key":"B128","doi-asserted-by":"publisher","first-page":"15252e108397","DOI":"10.15252\/embj.2021108397","article-title":"The PAX5-JAK2 Translocation Acts as Dual-Hit Mutation that Promotes Aggressive B-Cell Leukemia via Nuclear STAT5 Activation","volume":"10","author":"Jurado","year":"2022","journal-title":"EMBO J."},{"key":"B129","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2164-14-4","article-title":"Comprehensive Meta-Analysis of Signal Transducers and Activators of Transcription (STAT) Genomic Binding Patterns Discerns Cell-specific Cis-Regulatory Modules","volume":"14","author":"Kang","year":"2013","journal-title":"BMC Genomics"},{"key":"B130","doi-asserted-by":"publisher","first-page":"FRD10","DOI":"10.2217\/frd-2021-0006","article-title":"Treatment of PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Acute Lymphoblastic Leukemia with Stem Cell Transplantation","volume":"1","author":"Kaplan","year":"2021","journal-title":"Future Rare Dis."},{"key":"B131","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/acsmedchemlett.1c00058","article-title":"Degradation of Janus Kinase for Potential Application in Immune Response Therapeutics","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"B132","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/gcc.22251","article-title":"Identification ofSPAG9as a novelJAK2fusion Partner Gene in Pediatric Acute Lymphoblastic Leukemia with T(9;17)(p24;q21)","volume":"54","author":"Kawamura","year":"2015","journal-title":"Genes Chromosom. Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","article-title":"Specific JAK2 Mutation (JAK2R683) and Multiple Gene Deletions in Down Syndrome Acute Lymphoblastic Leukemia","volume":"113","author":"Kearney","year":"2009","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb.2519","article-title":"SOCS3 Binds Specific Receptor-JAK Complexes to Control Cytokine Signaling by Direct Kinase Inhibition","volume":"20","author":"Kershaw","year":"","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1042\/bst20130077","article-title":"Regulation of Janus Kinases by SOCS Proteins","volume":"41","author":"Kershaw","year":"","journal-title":"Biochem. Soc. Trans."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/srep14538","article-title":"Targeting Substrate-Site in Jak2 Kinase Prevents Emergence of Genetic Resistance","volume":"5","author":"Kesarwani","year":"2015","journal-title":"Sci. Rep."},{"key":"B137","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.seminhematol.2018.05.001","article-title":"Philadelphia Chromosome-like Acute Lymphoblastic Leukemia: A Review of the Genetic Basis, Clinical Features, and Therapeutic Options","volume":"55","author":"Khan","year":"2018","journal-title":"Seminars Hematol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1101\/gad.307504.117","article-title":"JAK2 Is Dispensable for Maintenance of JAK2 Mutant B-Cell Acute Lymphoblastic Leukemias","volume":"32","author":"Kim","year":"2018","journal-title":"Genes Dev."},{"key":"B139","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0092-8674(95)90351-8","article-title":"Specific Recruitment of SH-PTP1 to the Erythropoietin Receptor Causes Inactivation of JAK2 and Termination of Proliferative Signals","volume":"80","author":"Klingm\u00fcller","year":"1995","journal-title":"Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ajcp\/aqx005","article-title":"CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients","volume":"147","author":"Konoplev","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/nejmoa051113","article-title":"A Gain-Of-Function Mutation ofJAK2in Myeloproliferative Disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/s1470-2045(07)70206-1","article-title":"JAK2-V617F Mutation in a Patient with Philadelphia-chromosome-positive Chronic Myeloid Leukaemia","volume":"8","author":"Kr\u00e4mer","year":"2007","journal-title":"Lancet Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.leu.2404060","article-title":"Mutational Screen Reveals a Novel JAK2 Mutation, L611S, in a Child with Acute Lymphoblastic Leukemia","volume":"20","author":"Kratz","year":"2006","journal-title":"Leukemia"},{"key":"B145","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/stemcells.19-5-378","article-title":"SOCS Proteins: Negative Regulators of Cytokine Signaling","volume":"19","author":"Krebs","year":"2001","journal-title":"Stem Cells"},{"key":"B146","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of Prior JAK-Inhibitor Therapy with Ruxolitinib on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: a Study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1038\/onc.2009.107","article-title":"Kinase Drug Discovery Approaches in Chronic Myeloproliferative Disorders","volume":"28","author":"Kumar","year":"2009","journal-title":"Oncogene"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/cancers12082278","article-title":"Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis","volume":"12","author":"Kuykendall","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B149","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a Rux and a Hard Place: Evaluating Salvage Treatment and Outcomes in Myelofibrosis after Ruxolitinib Discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann. Hematol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F Mutation in De Novo Acute Myelogenous Leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"B152","doi-asserted-by":"publisher","first-page":"e58589","DOI":"10.1371\/journal.pone.0058589","article-title":"FOP Is a Centriolar Satellite Protein Involved in Ciliogenesis","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1038\/leu.2017.158","article-title":"Erratum: Rethinking JAK2 Inhibition: towards Novel Strategies of More Specific and Versatile Janus Kinase Inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1042\/bcj20160085","article-title":"Uncoupling JAK2 V617F Activation from Cytokine-Induced Signalling by Modulation of JH2 \u03b1C Helix","volume":"473","author":"Leroy","year":"2016","journal-title":"Biochem. J."},{"key":"B155","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000498945","article-title":"A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature","volume":"142","author":"Levavi","year":"2019","journal-title":"Acta Haematol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the Pathogenesis and Therapy of Myeloproliferative Disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B157","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myeloid Metaplasia with Myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: Transcriptional Control and Biological Impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-019-0166-y","article-title":"Targeted Therapies for Myeloproliferative Neoplasms","volume":"7","author":"Li","year":"2019","journal-title":"Biomark. Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijbiomac.2015.04.063","article-title":"Effects of the I682F Mutation on JAK2's Activity, Structure and Stability","volume":"79","author":"Li","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"e11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional Landscape of B Cell Precursor Acute Lymphoblastic Leukemia Based on an International Study of 1,223 Cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The Molecular Basis of JAK\/STAT Inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat. Commun."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/1535-7163.mct-07-2215","article-title":"LS104, a Non-ATP-competitive Small-Molecule Inhibitor of JAK2, Is Potently Inducing Apoptosis in JAK2V617F-Positive Cells","volume":"7","author":"Lipka","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1126\/science.283.5404.987","article-title":"Crystallographic Evidence for Preformed Dimers of Erythropoietin Receptor before Ligand Activation","volume":"283","author":"Livnah","year":"1999","journal-title":"Science"},{"key":"B165","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine Kinome Sequencing of Pediatric Acute Lymphoblastic Leukemia: a Report from the Children's Oncology Group TARGET Project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"key":"B166","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1074\/jbc.m707125200","article-title":"Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F","volume":"283","author":"Lu","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B167","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","article-title":"The Structural Basis of Janus Kinase 2 Inhibition by a Potent and Specific Pan-Janus Kinase Inhibitor","volume":"107","author":"Lucet","year":"2006","journal-title":"Blood"},{"key":"B168","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative Neoplasms Can Be Initiated from a Single Hematopoietic Stem Cell Expressing JAK2-V617f","volume":"211","author":"Lundberg","year":"2014","journal-title":"J. Exp. Med."},{"key":"B169","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B170","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood-2006-09-045963","article-title":"Novel Activating JAK2 Mutation in a Patient with Down Syndrome and B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"109","author":"Malinge","year":"2007","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.molcel.2005.02.021","article-title":"Structural Bases of Unphosphorylated STAT1 Association and Receptor Binding","volume":"17","author":"Mao","year":"2005","journal-title":"Mol. Cell"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e43437","DOI":"10.1371\/journal.pone.0043437","article-title":"Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor","volume":"7","author":"Marit","year":"2012","journal-title":"PLoS One"},{"key":"B173","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yexmp.2006.07.004","article-title":"Chronic Idiopathic Myelofibrosis (CIMF) Resulting from a Unique 3;9 Translocation Disrupting the Janus Kinase 2 (JAK2) Gene","volume":"81","author":"Mark","year":"2006","journal-title":"Exp. Mol. Pathology"},{"key":"B174","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3389\/fimmu.2020.01557","article-title":"Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer","volume":"11","author":"Markovic","year":"2020","journal-title":"Front. Immunol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 Mutations in the Kinase Domain Are Responsible for Hereditary Thrombocytosis and Are Resistant to JAK2 and HSP90 Inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"key":"B176","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0092-8674(91)90521-y","article-title":"The BCR Gene Encodes a Novel Serine\/threonine Kinase Activity within a Single Exon","volume":"67","author":"Maru","year":"1991","journal-title":"Cell"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1172\/jci42442","article-title":"HSP90 Is a Therapeutic Target in JAK2-dependent Myeloproliferative Neoplasms in Mice and Humans","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J. Clin. Invest."},{"key":"B178","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients with Myelofibrosis","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"106272","DOI":"10.1016\/j.leukres.2019.106272","article-title":"A Phase I Study of Panobinostat and Ruxolitinib in Patients with Primary Myelofibrosis (PMF) and Post-polycythemia Vera\/essential Thrombocythemia Myelofibrosis (Post-PV\/ET MF)","volume":"88","author":"Mascarenhas","year":"2020","journal-title":"Leukemia Res."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The Role of LNK\/SH2B3 Genetic Alterations in Myeloproliferative Neoplasms and Other Hematological Disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"key":"B181","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26328","article-title":"Integration of Ruxolitinib into Dose-Intensified Therapy Targeted against a Novel JAK2 F694L Mutation in B-Precursor Acute Lymphoblastic Leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"B183","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1582-4934.2011.01415.x","article-title":"Tyrosine Kinase Gene Fusions in Cancer: Translating Mechanisms into Targeted Therapies","volume":"16","author":"Medves","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"B184","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/jco.2017.73.4418","article-title":"SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib versus Ruxolitinib in Janus Kinase Inhibitor-Na\u00efve Patients with Myelofibrosis","volume":"35","author":"Mesa","year":"","journal-title":"Jco"},{"key":"B185","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/s2352-3026(17)30027-3","article-title":"Pacritinib versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): an International, Randomised, Phase 3 Trial","volume":"4","author":"Mesa","year":"","journal-title":"Lancet Haematol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"B187","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.hoc.2017.04.003","article-title":"Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms","volume":"31","author":"Meyer","year":"2017","journal-title":"Hematology\/Oncology Clin. N. Am."},{"key":"B188","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/leu.2009.194","article-title":"Oligomerization Inhibition, Combined with Allosteric Inhibition, Abrogates the Transformation Potential of T315I-Positive BCR\/ABL","volume":"23","author":"Mian","year":"2009","journal-title":"Leukemia"},{"key":"B189","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/BTT.S50734","article-title":"Resistant Mutations in CML and Ph(+)ALL - Role of Ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biologics"},{"key":"B190","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijbiomac.2021.08.194","article-title":"A Recombinant Antibody Fragment Directed to the Thymic Stromal Lymphopoietin Receptor (CRLF2) Efficiently Targets Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia","volume":"190","author":"Mohamed","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The Molecular Details of Cytokine Signaling via the JAK\/STAT Pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"B192","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic Myeloid Leukemia: Reminiscences and Dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"key":"B193","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in Myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-Progenitor- and Down Syndrome-Associated Acute Lymphoblastic Leukemia","volume":"41","author":"Mullighan","year":"","journal-title":"Nat. Genet."},{"key":"B195","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 Lymphoblastic Leukaemia Is Characterized by the Deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"B196","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/nejmoa0808253","article-title":"Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia","volume":"360","author":"Mullighan","year":"","journal-title":"N. Engl. J. Med."},{"key":"B197","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK Mutations in High-Risk Childhood Acute Lymphoblastic Leukemia","volume":"106","author":"Mullighan","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 Fusion in Myeloproliferative Disorders and Acute Erythroid Leukemia with T(8;9) Translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3390\/biology10090856","article-title":"The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation","volume":"10","author":"Musella","year":"2021","journal-title":"Biol. (Basel)"},{"key":"B200","doi-asserted-by":"publisher","first-page":"40782","DOI":"10.1074\/jbc.m507682200","article-title":"Structure of the Unphosphorylated STAT5a Dimer*","volume":"280","author":"Neculai","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B201","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s0092-8674(00)81168-x","article-title":"Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1124\/jpet.121.000686","article-title":"ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor for the Treatment of Allergic Diseases","volume":"10","author":"Numazaki","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B203","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2018.05.045","article-title":"Precision Medicine Approaches May Be the Future for CRLF2 Rearranged Down Syndrome Acute Lymphoblastic Leukaemia Patients","volume":"432","author":"Page","year":"2018","journal-title":"Cancer Lett."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after Ruxolitinib: Reasons for Discontinuation, Impact of Disease Phase, and Outcomes in 218 Patients with Myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"B205","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib Discontinuation Syndrome: Incidence, Risk Factors, and Management in 251 Patients with Myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J."},{"key":"B206","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/jco.2010.32.8021","article-title":"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"Jco"},{"key":"B207","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients with Primary or Secondary Myelofibrosis","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.leu.2404948","article-title":"JAK2 Inhibitor Therapy in Myeloproliferative Disorders: Rationale, Preclinical Studies and Ongoing Clinical Trials","volume":"22","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"B209","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s1470-2045(16)30558-7","article-title":"Ruxolitinib for the Treatment of Inadequately Controlled Polycythaemia Vera without Splenomegaly (RESPONSE-2): a Randomised, Open-Label, Phase 3b Study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/leu.2014.282","article-title":"Ruxolitinib and Survival Improvement in Patients with Myelofibrosis","volume":"29","author":"Passamonti","year":"2015","journal-title":"Leukemia"},{"key":"B211","doi-asserted-by":"publisher","first-page":"25971","DOI":"10.18632\/oncotarget.25411","article-title":"Surface Expression of Cytokine Receptor-like Factor 2 Increases Risk of Relapse in Pediatric Acute Lymphoblastic Leukemia Patients Harboring IKZF1 Deletions","volume":"9","author":"Pastorczak","year":"2018","journal-title":"Oncotarget"},{"key":"B212","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematology\/Oncology Clin. N. Am."},{"key":"B213","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1182\/blood.v90.7.2535","article-title":"Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of T(9; 12) in a Lymphoid and T(9; 15; 12) in a Myeloid Leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3324\/haematol.2019.220871","article-title":"Oncogenic Fusion Protein BCR-FGFR1 Requires the Breakpoint Cluster Region-Mediated Oligomerization and Chaperonin Hsp90 for Activation","volume":"105","author":"Peiris","year":"2020","journal-title":"Haematologica"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2012.5","article-title":"Prevalence and Dynamics of Bcr-Abl Kinase Domain Mutations during Imatinib Treatment Differ in Patients with Newly Diagnosed and Recurrent Bcr-Abl Positive Acute Lymphoblastic Leukemia","volume":"26","author":"Pfeifer","year":"2012","journal-title":"Leukemia"},{"key":"B216","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase Domain Mutations of BCR-ABL Frequently Precede Imatinib-Based Therapy and Give Rise to Relapse in Patients with De Novo Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/gcc.20585","article-title":"NovelSSBP2-JAK2fusion Gene Resulting from a t(5;9)(q14.1;p24.1) in Pre-B Acute Lymphocytic Leukemia","volume":"47","author":"Poitras","year":"2008","journal-title":"Genes Chromosom. Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B219","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia Chromosome-like Acute Lymphoblastic Leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B220","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL Using Chimeric Antigen Receptor-Expressing T Cells Targeting the TSLPR Oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"B221","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/tbj.14205","article-title":"Next Generation Sequencing of Breast Implant\u2010associated Anaplastic Large Cell Lymphomas Reveals a Novel STAT3\u2010JAK2 Fusion Among Other Activating Genetic Alterations within the JAK\u2010STAT Pathway","volume":"27","author":"Quesada","year":"2021","journal-title":"Breast J."},{"key":"B222","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical Characterization of the Selective JAK1\/2 Inhibitor INCB018424: Therapeutic Implications for the Treatment of Myeloproliferative Neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040800","article-title":"Janus Kinases in Leukemia","volume":"13","author":"Raivola","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B224","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable Kinase Gene Fusions in High-Risk B-ALL: a Study from the Children's Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"B225","doi-asserted-by":"publisher","first-page":"e05212","DOI":"10.1002\/ccr3.5212","article-title":"Sequential Allogeneic Transplantation and Ruxolitinib Maintenance for a Synchronous PCM1-JAK2 Positive Myeloid Sarcoma and Acute B-Lymphoblastic Leukemia","volume":"10","author":"Rizzuto","year":"2022","journal-title":"Clin. Case Rep."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1182\/bloodadvances.2017011296","article-title":"Oncogenic Role and Therapeutic Targeting of ABL-Class and JAK-STAT Activating Kinase Alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"","journal-title":"Blood Adv."},{"key":"B227","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/jco.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"","journal-title":"Jco"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/nejmoa1403088","article-title":"Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia","volume":"371","author":"Roberts","year":"","journal-title":"N. Engl. J. Med."},{"key":"B229","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"B230","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in Acute Lymphoblastic Leukaemia: Insights and Treatment Implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/jco.2014.55.4105","article-title":"Outcomes of Children with BCR-ABL1-like Acute Lymphoblastic Leukemia Treated with Risk-Directed Therapy Based on the Levels of Minimal Residual Disease","volume":"32","author":"Roberts","year":"","journal-title":"Jco"},{"key":"B232","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and Outcome Analyses of Ph-like ALL in NCI Standard-Risk Patients: a Report from the Children's Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"B233","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1158\/0008-5472.can-10-1528","article-title":"CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis: Figure 1","volume":"70","author":"Roll","year":"2010","journal-title":"Cancer Res."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2020.262691","article-title":"Persistence of Myelofibrosis Treated with Ruxolitinib: Biology and Clinical Implications","volume":"106","author":"Ross","year":"2021","journal-title":"haematol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, Present, and Future of Bcr-Abl Inhibitors: from Chemical Development to Clinical Efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"27251","DOI":"10.1074\/jbc.m501376200","article-title":"Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability","volume":"280","author":"Royer","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B237","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated Expression of Cytokine Receptor Gene, CRLF2, Is Involved in Lymphoid Transformation in B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"key":"B238","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cancergen.2017.07.008","article-title":"A Novel Somatic JAK2 Kinase-Domain Mutation in Pediatric Acute Lymphoblastic Leukemia with Rapid On-Treatment Development of LOH","author":"Sadras","year":"2017","journal-title":"Cancer Genet."},{"key":"B239","doi-asserted-by":"publisher","first-page":"47954","DOI":"10.1074\/jbc.m205156200","article-title":"The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-Inducible Activation of Signal Transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B240","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1128\/mcb.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 Tyrosine Kinase by its Pseudokinase Domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/gcc.22433","article-title":"Ph-like Acute Lymphoblastic Leukemia with a novelPAX5-KIDINS220fusion Transcript","volume":"56","author":"Sakamoto","year":"2017","journal-title":"Genes Chromosom. Cancer"},{"key":"B242","doi-asserted-by":"publisher","first-page":"e18522","DOI":"10.1371\/journal.pone.0018522","article-title":"Analysis of Jak2 Catalytic Function by Peptide Microarrays: the Role of the JH2 Domain and V617F Mutation","volume":"6","author":"Sanz","year":"2011","journal-title":"PLoS One"},{"key":"B243","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1101\/gad.1152403","article-title":"Opportunities and Challenges in the Development of Kinase Inhibitor Therapy for Cancer","volume":"17","author":"Sawyers","year":"2003","journal-title":"Genes Dev."},{"key":"B244","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1128\/mcb.17.9.5307","article-title":"Functional Differences between Stat3alpha and Stat3beta","volume":"17","author":"Schaefer","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.bi.64.070195.003201","article-title":"Transcriptional Responses to Polypeptide Ligands: The JAK-STAT Pathway","volume":"64","author":"Schindler","year":"1995","journal-title":"Annu. Rev. Biochem."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"B247","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2014-04-570960","article-title":"The Role of the Janus-Faced Transcription Factor PAX5-JAK2 in Acute Lymphoblastic Leukemia","volume":"125","author":"Schinnerl","year":"2015","journal-title":"Blood"},{"key":"B248","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/nejmoa1110169","article-title":"Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B249","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited Duration of Complete Remission on Ruxolitinib in Myeloid Neoplasms with PCM1-JAK2 and BCR-JAK2 Fusion Genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann. Hematol."},{"key":"B250","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to Tyrosine Kinase Inhibitors in Myeloid Neoplasms Associated with PCM1 \u2010 JAK2 , BCR\u2010JAK2 and ETV6\u2010ABL1 Fusion Genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1097\/hs9.0000000000000053","article-title":"Advances in B-Cell Precursor Acute Lymphoblastic Leukemia Genomics","volume":"2","author":"Schwab","year":"2018","journal-title":"Hemasphere"},{"key":"B252","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB Fusion in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Genetic Profile and Clinical Implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"key":"B253","doi-asserted-by":"publisher","first-page":"E4030","DOI":"10.1073\/pnas.1702489114","article-title":"Suppressors and Activators of JAK-STAT Signaling at Diagnosis and Relapse of Acute Lymphoblastic Leukemia in Down Syndrome","volume":"114","author":"Schwartzman","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B254","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cyto.2016.10.012","article-title":"The Promise of Janus Kinase Inhibitors in the Treatment of Hematological Malignancies","volume":"98","author":"Senkevitch","year":"2017","journal-title":"Cytokine"},{"key":"B255","doi-asserted-by":"publisher","first-page":"115326","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the Ubiquitin System: The Design and Physicochemical Optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"B256","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular Basis for Pseudokinase-dependent Autoinhibition of JAK2 Tyrosine Kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062193","article-title":"The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia","volume":"21","author":"Shiraz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B258","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11912-021-01087-x","article-title":"Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia","volume":"23","author":"Shoukier","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"B259","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1182\/blood-2015-01-621110","article-title":"Molecular Insights into Regulation of JAK2 in Myeloproliferative Neoplasms","volume":"125","author":"Silvennoinen","year":"","journal-title":"Blood"},{"key":"B260","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2015.06.010","article-title":"Targeting the Inactive Conformation of JAK2 in Hematological Malignancies","volume":"28","author":"Silvennoinen","year":"","journal-title":"Cancer Cell"},{"key":"B261","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/jep.s110702","article-title":"Comprehensive Kinase Profile of Pacritinib, a Nonmyelosuppressive Janus Kinase 2 Inhibitor","author":"Singer","year":"2016","journal-title":"Jep"},{"key":"B262","doi-asserted-by":"publisher","first-page":"e0222944","DOI":"10.1371\/journal.pone.0222944","article-title":"Comparative Phenotypic Profiling of the JAK2 Inhibitors Ruxolitinib, Fedratinib, Momelotinib, and Pacritinib Reveals Distinct Mechanistic Signatures","volume":"14","author":"Singer","year":"2019","journal-title":"PLoS One"},{"key":"B263","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive Review of JAK Inhibitors in Myeloproliferative Neoplasms","volume":"4","author":"Sonbol","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"B264","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cncr.28522","article-title":"Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia from the Imatinib to the Second-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are in the Type of Mutations, but Not in the Fr","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"B265","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10637-017-0495-3","article-title":"First-in-human Study of the Epichaperome Inhibitor PU-H71: Clinical Results and Metabolic Profile","volume":"36","author":"Speranza","year":"2018","journal-title":"Invest New Drugs"},{"key":"B266","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/43206","article-title":"A Family of Cytokine-Inducible Inhibitors of Signalling","volume":"387","author":"Starr","year":"1997","journal-title":"Nature"},{"key":"B267","doi-asserted-by":"publisher","first-page":"89923","DOI":"10.18632\/oncotarget.21027","article-title":"JAK2 Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"8","author":"Steeghs","year":"2017","journal-title":"Oncotarget"},{"key":"B268","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/1535-7163.mct-14-0647","article-title":"Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia","volume":"14","author":"Suryani","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B269","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2141.2011.08663.x","article-title":"Direct Activation of STAT5 by ETV6-LYN Fusion Protein Promotes Induction of Myeloproliferative Neoplasm with Myelofibrosis","volume":"153","author":"Takeda","year":"2011","journal-title":"Br. J. Haematol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a Newly Approved Treatment for Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"B271","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic Neoplasms with 9p24\/JAK2 Rearrangement: a Multicenter Study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod. Pathol."},{"key":"B272","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent Efficacy of Combined PI3K\/mTOR and JAK or ABL Inhibition in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia","volume":"129","author":"Tasian","year":"","journal-title":"Blood"},{"key":"B273","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269\/AALL1521): Dose-Finding Results from the Part 1 Safety Phase","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"key":"B274","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR Pathway Signaling Occurs in Human CRLF2-Rearranged B-Precursor Acute Lymphoblastic Leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"B275","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High Incidence of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Older Adults with B-ALL","volume":"31","author":"Tasian","year":"","journal-title":"Leukemia"},{"key":"B276","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia Chromosome-like Acute Lymphoblastic Leukemia","volume":"130","author":"Tasian","year":"","journal-title":"Blood"},{"key":"B277","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1615\/critrevoncog.v16.i1-2.30","article-title":"Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia","volume":"16","author":"Tasian","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"B278","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious Adverse Events during Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"B279","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute Lymphoblastic Leukemia: a Comprehensive Review and 2017 Update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"B280","doi-asserted-by":"publisher","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a Worldwide Hub of Protein Knowledge","volume":"47","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B281","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/leu.2012.293","article-title":"B-Lineage Transcription Factors and Cooperating Gene Lesions Required for Leukemia Development","volume":"27","author":"Tijchon","year":"2013","journal-title":"Leukemia"},{"key":"B282","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.m114.619502","article-title":"Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of its Pseudokinase Domain","volume":"290","author":"Tokarski","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B283","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/bloodadvances.2017014704","article-title":"Prognostic Impact of Kinase-Activating Fusions and IKZF1 Deletions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia","volume":"2","author":"Tran","year":"2018","journal-title":"Blood Adv."},{"key":"B284","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/asheducation-2016.1.561","article-title":"Ph-like Acute Lymphoblastic Leukemia","volume":"2016","author":"Tran","year":"20162016","journal-title":"ASH Educ. Book"},{"key":"B285","doi-asserted-by":"publisher","first-page":"eaat3834","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK Activation Loop Phosphorylation Is Linked to Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci. Adv."},{"key":"B286","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The Pseudokinase Domain of JAK2 Is a Dual-Specificity Protein Kinase that Negatively Regulates Cytokine Signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B287","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT Signaling in Hematological Malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"B288","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK Inhibitors for the Treatment of Myeloproliferative Neoplasms and Other Disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Res"},{"key":"B289","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1182\/blood-2012-02-413252","article-title":"Differences in Signaling through the B-Cell Leukemia Oncoprotein CRLF2 in Response to TSLP and through Mutant JAK2","volume":"120","author":"Van Bodegom","year":"2012","journal-title":"Blood"},{"key":"B290","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent Prognostic Value of BCR-ABL1-like Signature and IKZF1 Deletion, but Not High CRLF2 Expression, in Children with B-Cell Precursor ALL","volume":"122","author":"Van Der Veer","year":"2013","journal-title":"Blood"},{"key":"B291","doi-asserted-by":"publisher","first-page":"17211","DOI":"10.1038\/s41598-017-17620-7","article-title":"Virtual Screening for Inhibitors of the Human TSLP:TSLPR Interaction","volume":"7","author":"Van Rompaey","year":"2017","journal-title":"Sci. Rep."},{"key":"B292","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A Pooled Analysis of Overall Survival in COMFORT-I and COMFORT-II, 2 Randomized Phase III Trials of Ruxolitinib for the Treatment of Myelofibrosis","volume":"100","author":"Vannucchi","year":"","journal-title":"Haematologica"},{"key":"B293","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/nejmoa1409002","article-title":"Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"","journal-title":"N. Engl. J. Med."},{"key":"B294","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-020-00995-y","article-title":"Novel Therapeutics in Myeloproliferative Neoplasms","volume":"13","author":"Venugopal","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B295","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term Survival in Patients Treated with Ruxolitinib for Myelofibrosis: COMFORT-I and -II Pooled Analyses","volume":"10","author":"Verstovsek","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B296","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term Outcomes of 107 Patients with Myelofibrosis Receiving JAK1\/JAK2 Inhibitor Ruxolitinib: Survival Advantage in Comparison to Matched Historical Controls","volume":"120","author":"Verstovsek","year":"","journal-title":"Blood"},{"key":"B297","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/nejmoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"","journal-title":"N. Engl. J. Med."},{"key":"B298","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term Treatment with Ruxolitinib for Patients with Myelofibrosis: 5-year Update from the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial","volume":"10","author":"Verstovsek","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia","volume":"2021","author":"Verstovsek","year":"2021","journal-title":"haematol"},{"key":"B300","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/leu.2008.133","article-title":"Comparison of Mutated ABL1 and JAK2 as Oncogenes and Drug Targets in Myeloproliferative Disorders","volume":"22","author":"Walz","year":"2008","journal-title":"Leukemia"},{"key":"B301","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with Panobinostat and JAK2 Inhibitor TG101209 Attenuates JAK2V617F Levels and Signaling and Exerts Synergistic Cytotoxic Effects against Human Myeloproliferative Neoplastic Cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"B302","doi-asserted-by":"publisher","first-page":"e27159","DOI":"10.4161\/jkst.27159","article-title":"STAT5 in Hematopoietic Stem Cell Biology and Transplantation","volume":"2","author":"Wang","year":"2013","journal-title":"JAK-STAT"},{"key":"B303","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J. Exp. Med."},{"key":"B304","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F Oncogene Associated with Myeloproliferative Diseases Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"key":"B305","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.aaw3242","article-title":"Mechanism of Homodimeric Cytokine Receptor Activation and Dysregulation by Oncogenic Mutations","volume":"367","author":"Wilmes","year":"2020","journal-title":"Science"},{"key":"B306","doi-asserted-by":"publisher","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS Signaling Promotes Resistance to JAK Inhibitors by Suppressing BAD-Mediated Apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci. Signal"},{"key":"B307","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/leu.2015.53","article-title":"A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia","volume":"29","author":"Woessner","year":"2015","journal-title":"Leukemia"},{"key":"B308","doi-asserted-by":"publisher","first-page":"45722","DOI":"10.1074\/jbc.m105320200","article-title":"The Stat1 Binding Motif of the Interferon-\u03b3 Receptor Is Sufficient to Mediate Stat5 Activation and its Repression by SOCS3","volume":"276","author":"Woldman","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B309","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"key":"B310","doi-asserted-by":"publisher","first-page":"28830","DOI":"10.1074\/jbc.m201781200","article-title":"CD45 Controls Interleukin-4-Mediated IgE Class Switch Recombination in Human B Cells through its Function as a Janus Kinase Phosphatase","volume":"277","author":"Yamada","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B311","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjh.13757","article-title":"Identification of Novel Kinase Fusion Transcripts in Paediatric B Cell Precursor Acute Lymphoblastic Leukaemia withIKZF1deletion","volume":"171","author":"Yano","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B312","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/leu.2017.1","article-title":"Activating JAK2 Mutants Reveal Cytokine Receptor Coupling Differences that Impact Outcomes in Myeloproliferative Neoplasm","volume":"31","author":"Yao","year":"2017","journal-title":"Leukemia"},{"key":"B313","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-019-0182-z","article-title":"Interferon-\u03bb Orchestrates Innate and Adaptive Mucosal Immune Responses","volume":"19","author":"Ye","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B314","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional Screening Identifies CRLF2 in Precursor B-Cell Acute Lymphoblastic Leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B315","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"B316","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2249.2011.04328.x","article-title":"A Soluble Thymic Stromal Lymphopoietin (TSLP) Antagonist, TSLPR-Immunoglobulin, Reduces the Severity of Allergic Disease by Regulating Pulmonary Dendritic Cells","volume":"164","author":"Zhang","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"B317","doi-asserted-by":"publisher","first-page":"E2979","DOI":"10.1073\/pnas.1507812112","article-title":"Correction for Zhang et al., The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B318","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting Cancer with Small Molecule Kinase Inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"B319","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","article-title":"Prognostic Significance of CDKN2A\/B Deletions in Acute Lymphoblastic Leukaemia: a Meta-Analysis","volume":"51","author":"Zhang","year":"2019","journal-title":"Ann. Med."},{"key":"B320","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1073\/pnas.0611665104","article-title":"Identification of STAT3 as a Substrate of Receptor Protein Tyrosine Phosphatase T","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B321","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-019-0152-y","article-title":"Recent Advances on Blinatumomab for Acute Lymphoblastic Leukemia","volume":"8","author":"Zhao","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"B322","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1042\/bj20090615","article-title":"A Regulating Role of the JAK2 FERM Domain in Hyperactivation of JAK2(V617F)","volume":"426","author":"Zhao","year":"2010","journal-title":"Biochem. J."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.942053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T10:14:41Z","timestamp":1657620881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.942053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":322,"alternative-id":["10.3389\/fcell.2022.942053"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2022.942053","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"article-number":"942053"}}